MedTrace Logo

BRaziLian outcomE for metAStatic breasT Cancer

NCT05559528 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-09-29

No results posted yet for this study

Summary

Given the certain benefit in efficacy of adding CDK 4/6 inhibitor to first line endocrine therapy in metastatic breast cancer HR+ HER2- , the aim of this project is to evaluate whether patients without private health insurance may have worse outcomes than privately insured women due to limited access to such class of drugs during their treatments. Prospective observational study with 300 patients divided into two groups, one with patients from the public health system and the second with patients treated in the private service. Patients will be recruited in different regions of Brazil and will be followed for 24 months, stratified according to the use or not of the CDK 4/6 inhibitors.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Hospital do Coracao

    lead OTHER

Principal Investigators

  • Vanessa M Sanvido, PhD · Hospital do Coracao

  • Afonso CP Nazário, Professor · Hospital do Coracao

  • Luciola B Pontes, MD · Hospital do Coracao

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559528 on ClinicalTrials.gov